Donate
T1International Statement on Novo Nordisk and Sanofi Price Hikes

T1International Statement on Novo Nordisk and Sanofi Price Hikes

Facebook Google LinkedIn Twitter

Sanofi and Novo Nordisk are celebrating the New Year with fresh price hikes on their decades-old insulin products. “Sanofi increased the price of its three main insulin brands by between 4.4 %- 5.2 % last week, while Novo Nordisk increased the price of its insulin products by just under 5% on Tuesday,” the Financial Times article said. Once again, shareholder profits will be increased on the backs of people with diabetes.

Not one day goes by without T1International hearing from patients struggling to survive what should now officially be called the American insulin price crisis. Insulin rationing is already widespread and we are certain these actions by Sanofi and Novo Nordisk will worsen an already untenable situation. Americans are becoming literal refugees; unable to survive living in the country of their birth with a condition they acquired with through no fault of their own.

There are over 1 million people in America who have type 1 diabetes, all of whom need insulin to survive, in addition to insulin-dependent people with type 2 diabetes. They are co-workers, sisters, brothers, mothers and fathers. They are children. They all have stories, and insulin price gouging is shortening their lives.

Americans with type 1 diabetes need legal protection from price gouging, not platitudes from Donald Trump or Alex Azar, his Secretary of Health and Human Services and former Eli Lilly executive. Americans need affordable #insulin4all, not a circular passing of the blame between insurance, PBMs, and pharma while political representatives take big bucks from all three to turn a blind eye as Americans die from lack of centuries old therapy.

Take note: there is a growing movement of people following every move being made by the ‘big three’ and by politicians in response to the American insulin price crisis. This movement remains ready and able to support those willing to take action, like Minnesota Attorney General Keith Ellison’s investigation into the insulin cartel or the Kentucky State Legislature’s push for emergency access to insulin. Both actions, and many more, are being taken thanks to patients speaking out and fighting for change.

To all politicians and companies who think ‘business as usual’ still applies, our message is simple: time is up. Every day the #insulin4all Chapters are growing across the United States. People are organizing – in the media, in town halls, in legislatures and at company offices – and their voices will be heard.

Related posts:

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International is outraged, though not surprised, to see pharmaceutical companies once again put profit over human lives. On Tuesday, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the state of Minnesota to challenge the Alec Smith Insulin Affordability Act. Read more

T1International Statement on Insulin Manufacturer's Responses to COVID-19

T1International Statement on Insulin Manufacturer's Responses to COVID-19

The best way for insulin manufacturers to demonstrate their commitment to patient health would be for them to permanently lower their list price, which would make low-cost insulin easier to acquire and apply to every patient who needs it. Read more

T1International Statement on COVID-19

T1International Statement on COVID-19

As the world grapples with the effects of a global pandemic, the situation is evolving quickly and the short and long-term impacts are still unclear. What is clear is that the COVID-19 crisis stresses the need to approach healthcare as a human right. The crisis also emphasizes the need for international cooperation to fix global health problems. There must be global solidarity in the fight for #insulin4all and universal access to healthcare. Read more

T1International Statement on Brexit

T1International Statement on Brexit

We stand ready to hold the UK government to account on the provision of healthcare for UK citizens with type 1 diabetes over the coming months and years. We will strongly resist any erosion of the current provision of essential medicine and supplies, medical devices or support services for patients with type 1 diabetes in the UK. Read more

Sanofi's Lantus is Overpatented and Overpriced

Sanofi's Lantus is Overpatented and Overpriced

The diabetes community knows the sting of high drug prices. Over the years, the prices of essential insulin has increased at an alarming rate, requiring patients to jump through higher hoops and make more difficult decisions to keep up with costs. But how did we reach the point where so many people with diabetes cannot afford the medicines they need? Our new report on Lantus may provide some insight. Read more

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

I vow to continue to fight for the rights and lives of all people with diabetes. I am doing all this in honor of my son, Alec Raeshawn Smith. I invite Lilly to work with me and non-industry funded organizations like T1International so that we can find real solutions to ensure #insulin4all. Mr. Mason, I am still waiting to hear from you. Read more

Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers

The law firm Hagens Berman has filed a complaint against Eli Lilly, Novo Nordisk, and Sanofi, the ‘big three’ pharmaceutical companies that hold a near-monopoly on the insulin market. People living with type 1 diabetes will be the plaintiffs in this class action lawsuit, which alleges that Eli Lilly, Novo Nordisk and Sanofi have unjustly inflated their prices. Read more

Eli Lilly and Novo Nordisk: More Empty Promises

Eli Lilly and Novo Nordisk: More Empty Promises

Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more